Buscar
Mostrando ítems 1-4 de 4
Clinical landscape of LAG-3-targeted therapy
(Elsevier, 2022)
Artículo / Artikulua,
Lymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions. LAG-3 is considered a next-generation ...
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
(Springer Nature, 2021)
info:eu-repo/semantics/article,
Background: improving cancer immunotherapy long-term clinical benefit is a major priority. It has become apparent that multiple axes of immune suppression restrain the capacity of T cells to provide anti-tumour activity ...
Understanding LAG-3 Signaling
(MDPI, 2021)
info:eu-repo/semantics/article,
Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ...
Cutting-edge: preclinical and clinical development of the first approved LAG-3 inhibitor
(MDPI, 2022)
Artículo / Artikulua,
Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 (LAG-3) is one of the most important ...